BI Asset Management Fondsmaeglerselskab A S Reduces Stake in GSK PLC Sponsored ADR $GSK

BI Asset Management Fondsmaeglerselskab A S trimmed its position in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 67.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 40,056 shares of the pharmaceutical company’s stock after selling 81,193 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in GSK were worth $1,729,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Brighton Jones LLC purchased a new stake in shares of GSK in the 4th quarter worth about $528,000. AQR Capital Management LLC raised its position in GSK by 84.4% during the first quarter. AQR Capital Management LLC now owns 40,239 shares of the pharmaceutical company’s stock worth $1,559,000 after acquiring an additional 18,420 shares during the last quarter. Empowered Funds LLC lifted its holdings in shares of GSK by 2.1% in the first quarter. Empowered Funds LLC now owns 79,174 shares of the pharmaceutical company’s stock valued at $3,067,000 after purchasing an additional 1,598 shares in the last quarter. Trust Co. of Toledo NA OH grew its position in shares of GSK by 2.7% in the second quarter. Trust Co. of Toledo NA OH now owns 30,805 shares of the pharmaceutical company’s stock valued at $1,183,000 after purchasing an additional 797 shares during the last quarter. Finally, Yousif Capital Management LLC grew its position in shares of GSK by 7.9% in the second quarter. Yousif Capital Management LLC now owns 25,681 shares of the pharmaceutical company’s stock valued at $986,000 after purchasing an additional 1,875 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Performance

NYSE GSK opened at $60.14 on Monday. The business’s 50-day moving average price is $49.89 and its 200 day moving average price is $45.00. The company has a current ratio of 0.82, a quick ratio of 0.54 and a debt-to-equity ratio of 0.92. GSK PLC Sponsored ADR has a twelve month low of $32.38 and a twelve month high of $60.37. The company has a market capitalization of $122.59 billion, a PE ratio of 16.25, a price-to-earnings-growth ratio of 1.77 and a beta of 0.46.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 9th. Investors of record on Friday, February 20th will be given a $0.4856 dividend. This is a boost from GSK’s previous quarterly dividend of $0.42. This represents a $1.94 annualized dividend and a dividend yield of 3.2%. The ex-dividend date of this dividend is Friday, February 20th. GSK’s dividend payout ratio is 45.95%.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on GSK shares. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of GSK in a research note on Friday, January 16th. Cfra set a $53.00 price objective on GSK in a research report on Thursday, October 30th. Citigroup began coverage on GSK in a research note on Tuesday, January 27th. They set a “neutral” rating on the stock. Barclays downgraded shares of GSK from an “equal weight” rating to an “underweight” rating in a research note on Tuesday, January 6th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of GSK in a report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, GSK presently has a consensus rating of “Reduce” and a consensus target price of $44.13.

GSK News Summary

Here are the key news stories impacting GSK this week:

• Positive Sentiment: EU approval expands Nucala (mepolizumab) label to include add‑on maintenance treatment for COPD in adults — opens a large additional market for an existing respiratory franchise and supports incremental sales/volume in Europe. GSK wins EU nod to expand Nucala for COPD GSK Gets EU Approval for Expanded Use of Nucala in COPD
• Positive Sentiment: Shore Capital upgrades its outlook, saying GSK has effectively met its medium‑term plan early and calling a £40bn revenue target by 2031 credible; assigns a materially higher price target (2,500p), which could underpin further analyst upgrades and investor confidence. ShoreCap says GSK has cracked it and the £40bn prize is now in sight
• Positive Sentiment: GSK raised its quarterly dividend ~16.4% to $0.4856 (annualized yield ~3.2%) — attracts income investors and signals management confidence in cash flow. (Ex‑dividend Feb 20; pay Apr 9).
• Neutral Sentiment: Recent results and presentations (Q4 2025 results / Q3 2025 transcript) are being parsed by investors for guidance and margin trajectory; company messaging has been described as “solid,” which supports the bullish narrative but leaves sensitivity to longer‑term execution. GSK plc 2025 Q4 – Results – Earnings Call Presentation GSK Q3 2025 Earnings Call Transcript
• Neutral Sentiment: Analyst coverage shows divergence in fair‑value views as GSK’s pipeline and cash returns reshape models — this increases the likelihood of differing price targets and mixed short‑term analyst reactions. Why Analysts See GSK (LSE:GSK) Differently As The Fair Value Story Starts To Shift
• Neutral Sentiment: Macro/market context (e.g., software sell‑off, bond moves) is influencing sentiment toward defensive pharma names like GSK; this can amplify swings even when company fundamentals are steady. Software sell-off, corporate bonds & GSK
• Negative Sentiment: A law‑firm investor probe into the proposed acquisition of RAPT Therapeutics (deal consideration $58/share) questions adequacy of price/process — introduces potential legal/transactional risk and could delay or complicate the deal’s close. RAPT Therapeutics Investor Alert

Insider Transactions at GSK

In related news, major shareholder Plc Gsk purchased 1,470,000 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were bought at an average price of $19.00 per share, with a total value of $27,930,000.00. Following the completion of the purchase, the insider directly owned 18,245,691 shares in the company, valued at approximately $346,668,129. This trade represents a 8.76% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 10.00% of the company’s stock.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.